Entinostat, a histone deacetylase inhibitor, inhibits the proliferation and growth of Treg populations by activating STAT3 acetylation and reducing FoxP3 expression, suggesting a novel and effective approach to modulate the immune system and treat prostate cancer [86]. This evidence concerns the gene FOXP3 and prostate carcinoma.